Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$8.29
-$0.39(-7.98%)
At close: 4:00 PM EST
$8.29
-$0.39(-7.98%)
Day’s Range― - ―
52-Week Range$5.88 - $15.74
Previous CloseN/A
Volume345.04K
Average Volume (3M)642.70K
Market Cap
$454.44M
Enterprise Value$324.65M
Total Cash (Recent Filing)$333.32M
Total Debt (Recent Filing)$5.87M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding66,633,320
10 Day Avg. Volume423,909
30 Day Avg. Volume642,701
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-960.49
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$17.63Price Target Upside112.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & Multi‑year RunwayA large cash position with very low debt provides durable financial flexibility to fund clinical programs through multiple development milestones. This reduces near-term dilution risk, supports initiation of a registration‑enabling trial and OLE follow‑up, and buys time against regulatory or competitive delays.
Robust Phase Ib Clinical Efficacy And SafetyLarge, rapid HbF increases, early VOC reduction signals and a clean safety profile are durable indicators of biological plausibility and clinical benefit. These readouts strengthen the product's therapeutic rationale, improve chances of regulatory engagement, and support a competitive commercial positioning if confirmed in later trials.
Dedicated Discovery Capability And Scientific LeadershipBoard expertise in sickle cell disease and an internal discovery team sustain the company's ability to iterate on next‑generation oral HbF inducers. This builds a longer‑term competitive moat beyond a single asset, enabling pipeline replenishment and scientific continuity across development cycles.
Bears Say
Zero Revenue With Sizable Recurring LossesPersistent zero revenue and large net losses reflect the company’s pre‑commercial status and create ongoing funding dependence. Continued cash burn without diversification of income raises long‑term financing and execution risk, especially if trials extend or additional studies are required.
Regulatory Uncertainty On HbF As SurrogateUncertainty about HbF’s acceptability as a surrogate endpoint affects the regulatory pathway, required evidence and trial design. If regulators demand clinical outcomes, development timelines and costs could increase materially, altering the feasibility and timing of accelerated approval and commercialization.
Narrowed External Pipeline And Leadership Transition RiskUnwinding a licensed program reduces external diversification and potential milestone or royalty revenues, concentrating risk on core programs. Coupled with an upcoming CFO retirement and transition, this heightens execution and financing risk at a critical development stage when stable financial stewardship is important.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $5.88 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $454.44M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 67 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Apr 27, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 66,633,320 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.63 (112.61% Upside)
$17.63 (112.61% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 218.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.12%
12-Months-Change
Fundamentals
Return on Equity
-27.80%
Trailing 12-Months
Asset Growth
42.91%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for potociredir — notably a large, rapid increase in HbF, early VOC reduction signals and a clean safety profile — paired with a solid balance sheet and a clear plan for regulatory interactions and a potential registration-enabling trial. Offsetting risks include modestly higher operating losses and expenses, a quarterly cash decline (while runway remains into 2029), delayed availability of meaningful long-term OLE data (likely into 2027), ongoing regulatory uncertainty about surrogate endpoints and emerging competition in the oral HbF inducer space. Overall, the clinical and financial highlights outweigh the operational and regulatory uncertainties.View all FULC earnings summariesFULC Stock 12 Month Forecast
Average Price Target
$17.63
▲(112.61% Upside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.23% Insiders
8.15% Mutual Funds
58.96% Other Institutional Investors
11.09% Public Companies and
Individual Investors